NO20081233L - Albumin fusjonsproteiner - Google Patents

Albumin fusjonsproteiner

Info

Publication number
NO20081233L
NO20081233L NO20081233A NO20081233A NO20081233L NO 20081233 L NO20081233 L NO 20081233L NO 20081233 A NO20081233 A NO 20081233A NO 20081233 A NO20081233 A NO 20081233A NO 20081233 L NO20081233 L NO 20081233L
Authority
NO
Norway
Prior art keywords
albumin infusion
proteins
nucleic acids
vectors
fusion proteins
Prior art date
Application number
NO20081233A
Other languages
English (en)
Inventor
Adam Bell
Yanggu Shi
David Lafleur
Craig Rosen
Paul Moore
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NO20081233L publication Critical patent/NO20081233L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse omfatter albuminfusjonsproteinet. Nukleinsyremolekylene kodende for albuminfusjonsproteinene av oppfinnelsen er også omsluttet av oppfinnelsen, det er er også vektorer inneholdende disse nukleinsyrene, vertsceller transformert med disse nukleinsyrevektorene og fremgangsmåter for å lage albuminfusjonsproteiner ifølge oppfinnelsen, og å benytte disse nukleinsyrene, vektorene og/eller vertscellene. I tillegg omslutter den foreliggende oppfinnelsen farmasøytiske sammensetninger omfattende albuminfusjonsproteiner og deres fremgangsmåter og behandling, forebygging eller forbedring av sykdommer, lidelser eller tilstander ved å benytte albuminfusjonsproteiner av oppfinnelsen.
NO20081233A 2005-08-12 2008-03-10 Albumin fusjonsproteiner NO20081233L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
NO20081233L true NO20081233L (no) 2008-05-09

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081233A NO20081233L (no) 2005-08-12 2008-03-10 Albumin fusjonsproteiner

Country Status (13)

Country Link
EP (1) EP1924596A4 (no)
JP (1) JP2009504157A (no)
KR (1) KR20080071119A (no)
AU (1) AU2006280312A1 (no)
BR (1) BRPI0614761A2 (no)
CA (1) CA2618476A1 (no)
EC (1) ECSP088262A (no)
IL (1) IL189246A0 (no)
MA (1) MA29836B1 (no)
MX (1) MX2008001865A (no)
NO (1) NO20081233L (no)
TN (1) TNSN08064A1 (no)
WO (1) WO2007021494A2 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ES2484966T3 (es) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007258609B2 (en) 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2068905A4 (en) * 2006-09-14 2009-12-30 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
EP2450369A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
BRPI0915093A2 (pt) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos
MX2011007582A (es) 2009-01-16 2011-12-14 Teva Pharma Nuevas formulaciones estables de proteina de fusion recombinante de albumina humana-factor humano de estimulacion de colonias de granulocitos.
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
KR20100100254A (ko) * 2009-03-05 2010-09-15 (주)바이오큐어팜 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물
BR112012009450A2 (pt) * 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN107261119A (zh) * 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
RU2650784C2 (ru) 2011-05-05 2018-04-17 Альбумедикс А/С Варианты альбумина
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
CN103525695B (zh) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 便携式肾功能检测系统
JP6603128B2 (ja) 2012-07-11 2019-11-06 バイオベラティブ セラピューティクス インコーポレイテッド ＸＴＥＮおよびｖｏｎＷｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
HUE053136T2 (hu) 2013-02-15 2021-06-28 Bioverativ Therapeutics Inc Optimizált VIII. faktor gén
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
IL297611A (en) 2013-06-28 2022-12-01 Bioverativ Therapeutics Inc Binding of thrombin that degrades with castane and uses thereof
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
MY192481A (en) 2014-01-10 2022-08-23 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
CN105254766B (zh) * 2015-10-26 2018-10-16 中国航天员科研训练中心 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用
HUE059941T2 (hu) 2016-02-01 2023-01-28 Bioverativ Therapeutics Inc Optimalizált VIII-as faktor gének
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
EP3535585A1 (en) 2016-11-04 2019-09-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
US20190381149A1 (en) 2016-12-02 2019-12-19 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US20200031895A1 (en) 2016-12-16 2020-01-30 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
CN110831613A (zh) 2017-01-31 2020-02-21 比奥维拉迪维治疗股份有限公司 因子ix融合蛋白及其制备和使用方法
MA50141A (fr) * 2017-04-20 2020-07-29 Novo Nordisk As Procédés de purification de protéines de fusion d'albumine
US20210163986A1 (en) 2017-08-09 2021-06-03 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
MX2021006648A (es) 2018-12-06 2021-07-07 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor ix.
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
JPWO2022030580A1 (no) * 2020-08-06 2022-02-10
JP2024056667A (ja) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060071A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
PL1729795T3 (pl) * 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
JP2009504157A (ja) 2009-02-05
ECSP088262A (es) 2008-05-30
KR20080071119A (ko) 2008-08-01
BRPI0614761A2 (pt) 2009-05-19
AU2006280312A1 (en) 2007-02-22
EP1924596A4 (en) 2009-07-29
IL189246A0 (en) 2008-08-07
CA2618476A1 (en) 2007-02-22
MX2008001865A (es) 2008-04-15
MA29836B1 (fr) 2008-10-03
WO2007021494A3 (en) 2007-07-26
WO2007021494A2 (en) 2007-02-22
EP1924596A2 (en) 2008-05-28
TNSN08064A1 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
NO20081233L (no) Albumin fusjonsproteiner
NO20064059L (no) Albumin fusjonsproteiner
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2001079444A3 (en) Albumin fusion proteins
WO2007092772A3 (en) Protein formulations
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
ATE483027T1 (de) Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DK1888641T3 (da) Serumalbuminbindende proteiner
DK2369005T3 (da) Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
NO20052276L (no) Sirkulaert DNA-molekyl med en kondisjonell replikasjonsorigo, fremgangsmate for deres fremstilling og deres anvendelse i genterapi
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
WO2013003641A3 (en) Serpin fusion polypeptides and methods of use thereof
ATE439443T1 (de) NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
ATE486127T1 (de) Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
WO2008125280A3 (en) New modulating molecules for an improved regulated expression system
WO2007134907A3 (en) Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
WO2006110367A3 (en) Methods and compositions for mycoplasma toxins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application